The Safety and Efficacy of Zoledronic Acid in the Prevention of Cancer Therapy Induced Bone Loss

Breast Cancer Clinical Trial

Official title:

Zoledronic Acid in the Prevention of Cancer Therapy Induced Bone Loss

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00375505
• Other study ID #: CZOL446GDE21
• Status: Completed
• Phase: Phase 3
• First received: September 11, 2006
• Last updated: August 11, 2015
• Start date: October 2005
• Est. completion date: May 2014

Study information

• Verified date: August 2015
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationGermany: Federal Institute for Drugs and Medical Devices
• Study type: Interventional

Clinical Trial Summary

This study examines the safety and efficacy of zoledronic acid 4 mg., given every 3 months over 24 months (infusion at month 0, 3, 6, 9, 12, 15, 18 and 21) in improving bone mineral density in premenopausal women with hormone receptor negative breast cancer and adjuvant chemotherapeutic treatment

Recruitment information / eligibility

• Status: Completed
• Enrollment: 70
• Est. completion date: May 2014
• Est. primary completion date: May 2014
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Female patients with histologically confirmed incident invasive breast cancer (T1-4) with positive hormone receptor status (ER and/or PgR positive) and no evidence of regional lymph node metastasis (N0) or distant metastasis (M0)

• Patient has undergone complete primary tumor resection and axillary lymph node dissection less than 90 days before start of study drug treatment.

• Patient is premenopausal at diagnosis of breast cancer (spontaneous and regular menses with premenopausal estradiol levels (>10 ng/dL)

• Patient receives adjuvant standard chemoendocrine or endocrine therapy

• Bone density at study entry > -2.5 T-Score

Exclusion Criteria:

• History of treatment or disease affecting bone metabolism (e.g., Paget's disease, primary hyperparathyroidism), prior treatment with bisphosphonates or treatments for osteoporosis in addition to calcium and vitamin D

• Abnormal renal function

• Current active dental problems including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures, recent (within 6 weeks) or planned dental or jaw surgery (e.g. extraction, implants)

• Pregnancy or lactation

• Women of childbearing potential not applying a medically recognized form of contraception (i.e., oral contraceptives or implants, IUD, vaginal diaphragm or sponge, or condom with spermicide)

Other protocol-defined inclusion/exclusion criteria may apply

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Breast Cancer

Intervention

Drug:
• Zoledronic acid

• Placebo
Placebo

Locations

Country	Name	City	State
Germany	Novartis Investigative Site	Marburg

Sponsors (1)

Lead Sponsor	Collaborator
Novartis Pharmaceuticals

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Bone Mineral Density (BMD) Measured by Dual (Energy) X-ray Absorptiometry (DXA) at Lumbar Spine (L2-L4) From Baseline to Month 24	Bone mineral density (BMD) by DXA at lumbar spine (L2-L4); DXA assessments of the BMD at dual hips. (BMD). Two X-ray beams with different energy levels are aimed at the patient's bones. When soft tissue absorption is subtracted out, the BMD can be determined from the absorption of each beam by bone.	baseline, month 24	No
Primary	Change in Bone Mineral Density (BMD) at Lumbar Spine (L2-L4) From Baseline to Month 24 or Last Visit Measure by T-score	Bone mineral density (BMD) at lumbar spine (L2-L4) by T-score. Your T-score is the number of units that your bone density is above or below the average. -1 and above-bone density is considered normal; Between -1 and -2.5-is a sign of osteopenia, a condition in which bone density is below normal and may lead to osteoporosis. -2.5 and below-indicates that it is likely osteoporosis.	baseline, month 24	No
Primary	Change in Bone Mineral Density (BMD) at Lumbar Spine (L2-L4) From Baseline to Month 24 or Last Visit Measure by Z-score	Bone mineral density (BMD) at lumbar spine (L2-L4) measured by Z-score. If Z-score is -2 or lower, it may suggest that something other than aging is causing abnormal bone loss.	baseline, month 24	No
Primary	Percent Change in Bone Mineral Density for L2-L4 From Baseline to Month 24 or Last Visit	Bone mineral density (BMD) at lumbar spine (L2-L4) measured by using Lunar or Hologic dual-energy X-ray absorptiometry (DXA) Instruments. Measurements were done in the lumbar vertebrae (L2-L4)	baseline, month 24	No
Secondary	Percentage Change in Bone Mineral Density for Femoral Neck (Right and Left Side) From Baseline to Month 24	Bone mineral density (BMD) for femoral neck (right and left side) is measured by using Lunar or Hologic dual-energy X-ray absorptiometry (DXA) Instruments. Measurements were done on femoral neck (right and left side)	baseline, month 24	No
Secondary	Percentage Change in Bone Mineral Density for Total Femoral Neck (Right and Left Side) From Baseline to Month 24	Bone mineral density (BMD) for total femoral neck (right and left side) is measured by using Lunar or Hologic dual-energy X-ray absorptiometry (DXA) Instruments. Measurements were done on femoral neck (right and left side)	baseline, month 24	No
Secondary	Change in Bone Mineral Density Os Calcis (Right and Left Side) From Baseline to Month 24 as Measured by Speed of Sound (SOS)	Bone mineral density (BMD) for Os calcis (right and left side) is measured by SOS; SOS is a Quantitative ultrasonography scanning and measures bone mass and strength and assesses bone microarchitecture by detecting the transmission of high-frequency sound waves through bone.	baseline, month 24	No
Secondary	Change in Bone Mineral Density Os Calcis (Right and Left Side) From Baseline to Month 24 as Measured by Broadband Ultrasound Attenuation (BUA)	Bone mineral density (BMD) for Os calcis (right and left side) is measured by BUA; BUA is a Quantitative ultrasonography scanning and measures bone mass and strength and assesses bone microarchitecture by detecting the transmission of high-frequency sound waves through bone.	baseline, month 24	No
Secondary	Change in Bone Mineral Density Phalanges II, III, IV, and V From Baseline to Month 24 or Last Visit as Measured by Amplitude-dependent Speed of Sound (ADSOS)	Bone mineral density (BMD) for Phalanges II, III, IV, and V is measured by ADSOS; ADSOS is a Quantitative ultrasonography scanning and measures bone mass and strength and assesses bone microarchitecture by detecting the transmission of high-frequency sound waves through bone.	baseline, month 24	No
Secondary	Change in Serum CTX-carboxy-terminal Collagen Crosslinks From Baseline to Month 24	CTX is a telopeptide that can be used as a biomarker in the serum to measure the rate of bone turnover. The test used to detect the CTX marker is specific to bone resorption.	baseline, month 24	No
Secondary	Change in Aminoterminal Propeptide on Type I Procollagen (P1NP) From Baseline to Month 24	Change in Aminoterminal propeptide on type I procollagen (P1NP) from baseline to month 24. P1NP is a marker for bone formation. It is a specific indicator of type 1 collagen deposition. P1NP is increased in states of high bone turnover	baseline, month 24	No
Secondary	Change in Estradiol (E2) From Baseline to Month 24	Change in Estradiol from baseline to month 24	baseline, month 24	No
Secondary	Change in Follicle- Stimulating Hormone (FSH) From Baseline to Month 24	Change in Follicle- Stimulating Hormone (FSH) from baseline to month 24	baseline, month 24	No
Secondary	Change in Testosterone From Baseline to Month 24	Change in Testosterone from baseline to month 24	baseline, month 24	No
Secondary	Change in Sex Hormone Binding Globulin (SHGB) From Baseline to Month 24	Change in Sex Hormone binding globulin (SHGB) from baseline to month 24	baseline, month 24	No
Secondary	Change in Parathyroid Hormone (PTH) From Baseline to Month 24	Change in Parathyroid Hormone (PTH) from baseline to month 24	baseline, month 24	No
Secondary	Change in Vitamine D From Baseline to Month 24	Change in Vitamine D from baseline to month 24	baseline, month 24	No
Secondary	Change in Anti-Mueller Hormone (AMH) From Baseline to Month 24	Change in anti-Mueller hormone (AMH) from baseline to month 24	baseline, month 24	No
Secondary	Change in Inhibin A and Inhibin B From Baseline to Month 24	Change in Inhibin A and Inhibin B from baseline to month 24	baseline, month 24	No